Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040623 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02040623 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT02040623, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
* To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. * To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.
Interventions
- DRUG R348 Ophthalmic Solution, 0.2%
- DRUG R348 Ophthalmic Solution, 0.5%
- OTHER Placebo Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040623
The ClinicalTrials.gov registry entry for NCT02040623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which R348 Ophthalmic Solution, 0.2% is the first listed.
NCT02040623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02040623 about?
NCT02040623 is a clinical study titled "Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)". * To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. * To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.
What is the current status of trial NCT02040623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02040623?
The interventions under investigation include: R348 Ophthalmic Solution, 0.2% (DRUG), R348 Ophthalmic Solution, 0.5% (DRUG), Placebo Ophthalmic Solution (OTHER).
Who is sponsoring clinical trial NCT02040623?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.